Current development of diagnosis and treatments in neuroendocrine neoplasm

doi:10.3877/cma.j.issn.1674-6899.2019.06.016

Abstract

Abstract:

Neuroendocrine neoplasm arises from cells of the endocrine and nervous systems with functions of producing active amine and hormones. Most of NEN occur in digestive system especially in stomach, intestines and pancreas. The liver, lung and bone are the most common place for metastatic NEN. Because of lacking of specific symptoms, the prognosis of NEN is usually poor. The present study aimed at concluding at current diagnosis and treatment for NEN, providing references for patients with NEN.

Key words: Gastrointestinal tract, Pancreas, Neuroendocrine neoplasm

Jiakui Liang, Jie Wang, Jin Ji, Meiyuan Yang, Daorong Wang. Current development of diagnosis and treatments in neuroendocrine neoplasm[J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2019, 12(06): 380-384.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6899.2019.06.016

https://zhqjwkzz.cma-cmc.com.cn/EN/Y2019/V12/I06/380

References 43

[1]	Aaron I Vinik, Celine Chaya. Clinical presentation and diagnosis of neuroendocrine tumors[J]. Hematology/oncology Clinics of North America, 2015, 30(1)：21-48.
[2]	Merav Fraenkel, Antongiulio Faggiano, Gerlof D Valk. Epidemiology of neuroendocrine tumors[J]. Frontiers of Hormone Research，2015, 44：1-23.DOI： 10.1159/000381970.
[3]	Daniel Benchimol, Amine Rahili. Tumors of the colon and rectum[J]. La Revue Du Praticien, 2002, 52(10)：1105-1114.
[4]	宋玉立，陈原稼，陈浩，等．国际上胃肠胰神经内分泌肿瘤两种分期、分级异同的比较和解读[J]. 中华消化杂志，2014，34(2)：136-139.
[5]	Yao JC, Hassan M, Phan A，et al. One hundred years after "carcinoid" ：epidemiology of and prognostic factors for neuroendocrine tumors in 35825 cases in the united states[J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology，2008，26(18)：3063-3072.
[6]	唐承薇，郭林杰. 我国胃肠胰神经内分泌肿瘤临床现状分析[J]. 中国实用外科杂志，2014，34(6): 490-492.
[7]	Wan YH，Lin Y，Xue L，et al. Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms：a single－institution analysis (1995－2012) in south china[J]. BMC Endocrine Disorders, 2012，12(1): 30-30.
[8]	Maxwell JE，Howe JR.Imaging in neuroendocrine tumors: an update for the clinician[J]．International Journal of Endocrine Oncology，2015，2(2)：159-168.
[9]	Brabander Tessa，Kwekkeboom Dik J，Feelders Richard A，et al. Nuclear medicine imaging of neuroendocrine tumors[J]. Frontiers of hormone research，2015，44: 73-87.DOI： 10.1159/000382059.
[10]	Mouen A Khashab, Elaine Yong, Anne Marie Lennon，et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors[J]. Gastrointestinal Endoscopy, 2011，73(4)：691-696.
[11]	咎宁，范娟. CT灌注成像在恶性肿瘤临床应用中的进展[J]. 肿瘤预防与治疗，2016，29(1): 59-63.
[12]	徐志明，曾蒙苏. 胰腺神经内分泌瘤的MRI特点[J]. 解放军医学院学报，2009，30(4): 490-492.
[13]	李景南，张红杰，陈洁，等. 胃肠胰神经内分泌肿瘤内科诊治若干建议[J]. 中华消化杂志，2014, 34(6): 361-367.
[14]	Hofman M, Kong G, Neels O, et al.High management impact of Ga－68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours[J]. Journal of Medical Imaging & Radiation Oncology, 2012，56(1): 40-47.
[15]	中国胃肠胰神经内分泌肿瘤病理专家组．中国胃肠胰神经内分泌肿瘤病理学诊断共识[J]. 中华病理学杂志，2011，40(4): 257-262.
[16]	Insabato Luigi. An update on the pathology of neuroendocrine tumors[J]. Frontiers in Bioscience，2016，8(1)：1-12.
[17]	Wang YH, Yang QC, Lin Y, et al. Chromogranin a as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm[J]. Medicine, 2014. 93(27)：32-47.
[18]	Massironi S, Rossi RE, Casazza G，et al. Chromogranin a in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution[J]. Neuroendocrinology，2014，100(2): 240-249.
[19]	Panel Members of Standardization for Diagnostic Tumor Pathology. Standardization for diagnostic tumor pathology: gastroenteropancreatic neuroendocrine neoplasm[J]．Zhonghua Bing Li Xue Za Zhi，2017，46(2)：76-78.
[20]	Khan MS, Kirkwood A, Tsigani T, et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors[J]．J Clin Oncol，2013，31(3)：365-372.
[21]	Frilling A, Modlin IM, Kidd M, et al.Recommendations for management of patients with neuroendocrine liver metastases[J]. Lancet Oncology, 2014，15(1): 18-21.
[22]	Delle FG, Kwekkeboom DJ，Van Cutsem E, et al. ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms[J]. Neuroendocrinology, 2012，95(2): 74-87.
[23]	Pape UF, Perren A, Niederle B, et al. ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno－ileum and the appendix including goblet cell carcinomas[J]. Neuroendocrinology, 2012，95(2): 135-156.
[24]	O′Toole Dermot，Kianmanesh Reza，Caplin Martyn.ENETS 2016 consensus guidelines for the management of patients with digestive neuroendocrine tumors: an update[J]. Neuroendocrinology，2016，103(2)：117-118.
[25]	楼文晖. 《中国胃肠胰神经内分泌肿瘤专家共识》胰腺神经内分泌肿瘤外科治疗部分解读[J]. 中国实用外科杂志，2014，34(6)：482-483.
[26]	Turner NC, Strauss SJ, Sarker D, et al.Chemotherapy with 5－fluorouracil, cisplatin and streptozocin for neuroendocrine tumours[J]. British Journal of Cancer, 2010，102(7): 1106-1112.
[27]	CSCO神经内分泌肿瘤专家委员会．中国胃肠胰神经内分泌肿瘤专家共识[J]. 临床肿瘤学杂志，2013，18(9): 815-832.
[28]	Oberg K, LambertsSW. Somatostatinanalogues inacromegaly and gastroentero pancreatic neuroendocrine tumours：past，present and future[J]．Endocr Relat Cancer，2016，23(12)：551-566.
[29]	Oberg K, K vols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for them anagement of neu roendocrinetumors of the gastroenteropancreatic system [J] . A nn On col，2004，15(6)：966-973.
[30]	Rinke A, Müller HH, Schadebrittinger C. Placebo－controlled, double－blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the promid study group[J]．Neuroendocrinology, 2009, 27(28)：4656-4663.
[31]	Papaxoinis G, Syrigos K, Saif MW. Novel therapeutic approaches and mechanisms in neuroendocrine tumors：the role of targeted agents[J]. Discov Med，2016，21(117)：391-402.
[32]	Massironi S，Conte D，Rossi RE.Somatostatinanalogues in functioninggastroenteropancreatic neuroendocrine tumours：literature review，clinical recommendations and schedules[J]. Scand J Gastroenterol，2016，51(5)：513-523.
[33]	Lee MS，O′Neil BH. Summary of emerging personalized medicine in neuroendocrine tumors: are we on track[J]. Journal of Gastrointestinal Oncology, 2016，7(5): 804-818.
[34]	Fazio N, Abdel－Rahman O, Spada F, et al. RAF signaling in neuroendocrine neoplasms: from bench to bedside[J]. Cancer Treatment Reviews, 2014. 40(8): 974-979.
[35]	Jiang X, Cao Y, Li F, et al. Targeting β－catenin signaling for therapeutic intervention in MEN1－deficient pancreatic neuroendocrine tumours[J]. Nature Communications, 2014，5: 58-69.DOI： 10.1038/ncomms6809.
[36]	Sebastian Krug, Benjamin Kuehnemuth, Heidi Griesmann，et al. CUX1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms[J]. Endocrine Related Cancer, 2014, 21(6): 879-890.
[37]	Fendrich V, Lopez CL, Manoharan J，et al. Enalapril and ass inhibit tumor growth in a transgenic mouse model of islet cell tumors[J]. Endocrine Related Cancer，2014，21(5)：813-824.
[38]	Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendoendocrine(includingcarcinoid)tumours(NETs)[J]．Gut，2012，61(1)：6-32.
[39]	Bodei L. Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer[J]. Seminars in Nuclear Medicine, 2016，46(3): 225-238.
[40]	Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non－functional pancreatic neuroendocrine tumors[J]. Neuroendocrinology, 2016, 103(2)：153-171.
[41]	Sabet A, Ezziddin K, Pape UF, et al. Long－term hematotoxicity after peptide receptor radionuclide therapy with 177lu－octreotate[J]. Journal of Nuclear Medicine, 2013，54(11): 1857-1861.
[42]	Erhas B, Tuncel M. Renal function assessment during peptide receptor radionuclide therapy[J]. Seminars in Nuclear Medicine, 2016，46(5): 462-478.
[43]	Jonathan Strosberg, Nancy Gardner, Larry Kvols. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid－gut[J]. Neuroendocrinology, 2009, 89(4)：471-476.

Please choose a citation manager

Content to export